date: 2023-03-14T04:38:41Z
pdf:unmappedUnicodeCharsPerPage: 0
pdf:PDFVersion: 1.7
pdf:docinfo:title: Safety and Immunogenicity of Recombinant Bacille Calmette-Guérin Strain VPM1002 and Its Derivatives in a Goat Model
xmp:CreatorTool: LaTeX with hyperref
Keywords: VPM1002; Bacille Calmette-Guérin; immune response; tuberculosis vaccine; goat model
access_permission:modify_annotations: true
access_permission:can_print_degraded: true
subject: A more effective vaccine against tuberculosis than Bacille Calmette-Guérin (BCG) is urgently needed. BCG derived recombinant VPM1002 has been found to be more efficacious and safer than the parental strain in mice models. Newer candidates, such as VPM1002 pdx1 (PDX) and VPM1002 nuoG (NUOG), were generated to further improve the safety profile or efficacy of the vaccine. Herein, we assessed the safety and immunogenicity of VPM1002 and its derivatives, PDX and NUOG, in juvenile goats. Vaccination did not affect the goats? health in regards to clinical/hematological features. However, all three tested vaccine candidates and BCG induced granulomas at the site of injection, with some of the nodules developing ulcerations approximately one month post-vaccination. Viable vaccine strains were cultured from the injection site wounds in a few NUOG- and PDX- vaccinated animals. At necropsy (127 days post-vaccination), BCG, VPM1002, and NUOG, but not PDX, still persisted at the injection granulomas. All strains, apart from NUOG, induced granuloma formation only in the lymph nodes draining the injection site. In one animal, the administered BCG strain was recovered from the mediastinal lymph nodes. Interferon gamma (IFN-) release assay showed that VPM1002 and NUOG induced a strong antigen-specific response comparable to that elicited by BCG, while the response to PDX was delayed. Flow cytometry analysis of IFN- production by CD4+, CD8+, and  T cells showed that CD4+ T cells of VPM1002- and NUOG-vaccinated goats produced more IFN- compared to BCG-vaccinated and mock-treated animals. In summary, the subcutaneous application of VPM1002 and NUOG induced anti-tuberculous immunity, while exhibiting a comparable safety profile to BCG in goats.
dc:creator: Julia Figl, Heike Köhler, Nadine Wedlich, Elisabeth M. Liebler-Tenorio, Leander Grode, Gerald Parzmair, Gopinath Krishnamoorthy, Natalie E. Nieuwenhuizen, Stefan H. E. Kaufmann and Christian Menge
dcterms:created: 2023-03-14T04:32:08Z
Last-Modified: 2023-03-14T04:38:41Z
dcterms:modified: 2023-03-14T04:38:41Z
dc:format: application/pdf; version=1.7
title: Safety and Immunogenicity of Recombinant Bacille Calmette-Guérin Strain VPM1002 and Its Derivatives in a Goat Model
Last-Save-Date: 2023-03-14T04:38:41Z
pdf:docinfo:creator_tool: LaTeX with hyperref
access_permission:fill_in_form: true
pdf:docinfo:keywords: VPM1002; Bacille Calmette-Guérin; immune response; tuberculosis vaccine; goat model
pdf:docinfo:modified: 2023-03-14T04:38:41Z
meta:save-date: 2023-03-14T04:38:41Z
pdf:encrypted: false
dc:title: Safety and Immunogenicity of Recombinant Bacille Calmette-Guérin Strain VPM1002 and Its Derivatives in a Goat Model
modified: 2023-03-14T04:38:41Z
cp:subject: A more effective vaccine against tuberculosis than Bacille Calmette-Guérin (BCG) is urgently needed. BCG derived recombinant VPM1002 has been found to be more efficacious and safer than the parental strain in mice models. Newer candidates, such as VPM1002 pdx1 (PDX) and VPM1002 nuoG (NUOG), were generated to further improve the safety profile or efficacy of the vaccine. Herein, we assessed the safety and immunogenicity of VPM1002 and its derivatives, PDX and NUOG, in juvenile goats. Vaccination did not affect the goats? health in regards to clinical/hematological features. However, all three tested vaccine candidates and BCG induced granulomas at the site of injection, with some of the nodules developing ulcerations approximately one month post-vaccination. Viable vaccine strains were cultured from the injection site wounds in a few NUOG- and PDX- vaccinated animals. At necropsy (127 days post-vaccination), BCG, VPM1002, and NUOG, but not PDX, still persisted at the injection granulomas. All strains, apart from NUOG, induced granuloma formation only in the lymph nodes draining the injection site. In one animal, the administered BCG strain was recovered from the mediastinal lymph nodes. Interferon gamma (IFN-) release assay showed that VPM1002 and NUOG induced a strong antigen-specific response comparable to that elicited by BCG, while the response to PDX was delayed. Flow cytometry analysis of IFN- production by CD4+, CD8+, and  T cells showed that CD4+ T cells of VPM1002- and NUOG-vaccinated goats produced more IFN- compared to BCG-vaccinated and mock-treated animals. In summary, the subcutaneous application of VPM1002 and NUOG induced anti-tuberculous immunity, while exhibiting a comparable safety profile to BCG in goats.
pdf:docinfo:subject: A more effective vaccine against tuberculosis than Bacille Calmette-Guérin (BCG) is urgently needed. BCG derived recombinant VPM1002 has been found to be more efficacious and safer than the parental strain in mice models. Newer candidates, such as VPM1002 pdx1 (PDX) and VPM1002 nuoG (NUOG), were generated to further improve the safety profile or efficacy of the vaccine. Herein, we assessed the safety and immunogenicity of VPM1002 and its derivatives, PDX and NUOG, in juvenile goats. Vaccination did not affect the goats? health in regards to clinical/hematological features. However, all three tested vaccine candidates and BCG induced granulomas at the site of injection, with some of the nodules developing ulcerations approximately one month post-vaccination. Viable vaccine strains were cultured from the injection site wounds in a few NUOG- and PDX- vaccinated animals. At necropsy (127 days post-vaccination), BCG, VPM1002, and NUOG, but not PDX, still persisted at the injection granulomas. All strains, apart from NUOG, induced granuloma formation only in the lymph nodes draining the injection site. In one animal, the administered BCG strain was recovered from the mediastinal lymph nodes. Interferon gamma (IFN-) release assay showed that VPM1002 and NUOG induced a strong antigen-specific response comparable to that elicited by BCG, while the response to PDX was delayed. Flow cytometry analysis of IFN- production by CD4+, CD8+, and  T cells showed that CD4+ T cells of VPM1002- and NUOG-vaccinated goats produced more IFN- compared to BCG-vaccinated and mock-treated animals. In summary, the subcutaneous application of VPM1002 and NUOG induced anti-tuberculous immunity, while exhibiting a comparable safety profile to BCG in goats.
Content-Type: application/pdf
pdf:docinfo:creator: Julia Figl, Heike Köhler, Nadine Wedlich, Elisabeth M. Liebler-Tenorio, Leander Grode, Gerald Parzmair, Gopinath Krishnamoorthy, Natalie E. Nieuwenhuizen, Stefan H. E. Kaufmann and Christian Menge
X-Parsed-By: org.apache.tika.parser.DefaultParser
creator: Julia Figl, Heike Köhler, Nadine Wedlich, Elisabeth M. Liebler-Tenorio, Leander Grode, Gerald Parzmair, Gopinath Krishnamoorthy, Natalie E. Nieuwenhuizen, Stefan H. E. Kaufmann and Christian Menge
meta:author: Julia Figl, Heike Köhler, Nadine Wedlich, Elisabeth M. Liebler-Tenorio, Leander Grode, Gerald Parzmair, Gopinath Krishnamoorthy, Natalie E. Nieuwenhuizen, Stefan H. E. Kaufmann and Christian Menge
dc:subject: VPM1002; Bacille Calmette-Guérin; immune response; tuberculosis vaccine; goat model
meta:creation-date: 2023-03-14T04:32:08Z
created: 2023-03-14T04:32:08Z
access_permission:extract_for_accessibility: true
access_permission:assemble_document: true
xmpTPg:NPages: 25
Creation-Date: 2023-03-14T04:32:08Z
pdf:charsPerPage: 3788
access_permission:extract_content: true
access_permission:can_print: true
meta:keyword: VPM1002; Bacille Calmette-Guérin; immune response; tuberculosis vaccine; goat model
Author: Julia Figl, Heike Köhler, Nadine Wedlich, Elisabeth M. Liebler-Tenorio, Leander Grode, Gerald Parzmair, Gopinath Krishnamoorthy, Natalie E. Nieuwenhuizen, Stefan H. E. Kaufmann and Christian Menge
producer: pdfTeX-1.40.21
access_permission:can_modify: true
pdf:docinfo:producer: pdfTeX-1.40.21
pdf:docinfo:created: 2023-03-14T04:32:08Z